Cumberland Pharmaceuticals 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cumberland Pharmaceuticals closed its strategic transaction with Apotex Health on July 1st, receiving $100 million at closing in exchange for integrating its commercial products and organization into Apotex’s U.S.-branded business.
- At September 30th, Cumberland reported total assets of $114 million, cash and cash equivalents of $80.6 million, total liabilities of $41.2 million, shareholders’ equity of $72.5 million, and no debt.
- 3rd quarter net income was $77.8 million, including the gain on the sale of the commercial products; interest income was $0.8 million for the quarter.
- The board declared and funded a special dividend of $1.50 per share, totaling $22 million based on approximately 15 million shares outstanding.
- The company reported that its share repurchase initiative, authorized by the board, has begun implementation.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to Cumberland Pharmaceuticals' Third Quarter 2026 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for one year from today's date. I would now like to turn it over to Emily Kent from the Dalton Agency, who handles Cumberland's communications.
Emily, please proceed. Hello, everyone, and thank you for joining us today.
This afternoon, Cumberland issued a press release announcing its third quarter financial results. The release also provided an overall company update, including key recent developments. The release, which includes the related financial tables, can be found on the company's website at www.cumberlandpharma.com. During today's call, management will share an overview of those financial results and company update, including recent developments and a discussion of Cumberland's clinical pipeline. Participating in today's call are A.J. Kazimi, Cumberland's Chief Executive Officer, Todd Anthony, Senior Vice President Operations and Chief Compliance Officer, and John Hamm, Senior Vice President Accounting and Finance and Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Litigation Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties.
There are many factors that could affect Cumberland's future results, including economic downturns, international conflicts, trade restrictions, natural disasters, public health epidemics, and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's annual report on Form 10-K and any subsequent updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. During today's call, there will be references to Cumberland's new product candidates, including their development and associated regulatory activities. Despite the company's best efforts, actual results may differ materially from expectations, so information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. For more information, please visit the corporate website at www.cumberlandpharma.com.
With that introduction, I'll turn the call over to Cumberland's Chief Executive Officer, A.J.
Kazimi. Thank you, Emily, and good afternoon, everyone.
We appreciate you joining us today as we review Cumberland's third quarter results, which represent our first period of operations following the close of our strategic transaction. Recall in April this year, we announced an agreement with Apotex Health, the largest pharma company based in Canada, and we agreed to integrate our commercial products and organization into their U.S. branded business in exchange for $100 million cash at closing. In June, our shareholders overwhelmingly approved the transaction, and July 1, we successfully closed and received the payment. Our third quarter balance sheet reflects the financial impact of this transaction on our business. Total assets grew to $114 million, while total liabilities decreased to $42 million. The impact of those changes resulted in shareholders' equity of $72 million, an increase of nearly $48 million.
At the end of the quarter, we held $80.6 million in cash and investments with no debt. Also, please note that in addition to the consideration at closing, we will receive $11 million for inventory and transition services during the following 12 months. That funding, combined with our interest income, will more than cover our operating expenses during the 12-month post-transaction period. This transformational transaction strengthened Cumberland's financial position, unlocked substantial value for our shareholders, and established a solid foundation for the next phase of the company's evolution. During the third quarter, we took a fresh look at our strategy, which now centers on advancing our late-stage development programs. Our newly refined mission statement reflects our new direction and focus, advancing new therapies that address significant unmet medical needs.
This mission guides our next chapter as an innovation-focused biopharmaceutical company, developing new products primarily for rare diseases, and it directs our resources and expertise towards advancing our clinical-stage pipeline, which we believe the most valuable part of our business, and the greatest source of potential long-term value for our shareholders. It builds upon our core competencies, which are drug development and corporate development. We intend to apply our deep experience in developing, registering, and commercializing new branded products in pursuing this refined mission. Our team delivered FDA approvals for Acetadote and CALDOLOR, then added more FDA approvals for a series of new indications for those brands. They also successfully registered with FDA a series of manufacturing facilities worldwide for the supply of our portfolio of products.
Our ability to follow those accomplishments by creating significant resulting revenue streams for the brands, and then monetizing the resulting value through our strategic transaction now applies directly to our ability to execute on our new strategy. Going forward, our key objectives include progressing our pipeline in a cost-efficient manner to deliver high-quality results, achieving the needed approvals to market our products, pursuing alternatives for their commercialization, increasing awareness of our company in order to build share value, and continuing to support and motivate our dedicated, highly productive team. Our key development programs are based on our first new chemical entity, ifetroban. It is a potent and selective thromboxane receptor antagonist that has now been administered to approximately 1,400 subjects across 30 clinical studies, demonstrating a strong safety profile. Leading the way is our Duchenne muscular dystrophy, or DMD, program.
Duchenne muscular dystrophy is a rare, fatal genetic neuromuscular disease that results in deterioration of the skeletal heart and lung muscles. Our ifetroban product candidate is designed to specifically preserve cardiac function and improve outcomes for patients living with DMD-associated cardiomyopathy. There are no approved therapies specifically targeting DMD patients' heart disease, which is now the leading cause of their death. Given the urgency in providing a treatment for these patients, we recently announced our decision to submit a new drug application for our DMD program following a pre-NDA meeting with the FDA this fall. We are proposing our FIGHT DMD trial as the pivotal study, combined with comparison data from two natural history databases to support a traditional approval.
In that trial, high-dose ifetroban resulted in a significant 5.4 percentage point improvement in the left ventricular ejection fraction compared with a control group of placebo-treated patients combined with propensity score-matched natural history patients and a p-value of 0.002. Ifetroban has received FDA orphan drug, rare pediatric disease, and fast-track designations for this program. The FDA has also conditionally accepted DYSCORBAN as the proprietary name for the product. Following the pre-NDA meeting, FDA granted us a rolling review of our approval submission. While preparation of the NDA is now well underway, the planned contents will include data and analysis from the FIGHT DMD clinical trial, data from two natural history databases of DMD patients, preclinical data published in the Journal of the American Heart Association, manufacturing information, and an extensive safety database.
It will also involve the additional analysis and data that FDA requested at our pre-NDA meeting, which includes data from the clinical study's open-label extension. All patients who completed the 12-month treatment period elected to continue to receive ifetroban. While that data was not part of the study's analysis, the resulting 24-month and 36-month data is currently being gathered and monitored for analysis and reporting. We expect to announce the beginning of the rolling submission, followed by an announcement when the submission is then completed. Meanwhile, we are also advancing ifetroban for other conditions which also have limited treatment options. Now I would like to turn it over to Todd Anthony to discuss those programs.
Todd? Well, thank you, A.J.
I will begin with our systemic sclerosis, or SSc, program. We have been studying ifetroban in patients with systemic sclerosis, a rare autoimmune disease characterized by progressive vascular dysfunction that can affect multiple organs throughout the body. We recently announced top-line results from our phase IIa ASSIST-SSc trial. Ifetroban was generally well tolerated with a safety profile consistent with our prior experience and no serious adverse events during the 12-month period related to study drug. The trial was not designed or powered to evaluate efficacy. Next, we plan to finalize and submit the clinical study report to the FDA. We also plan to complete correlative biomarker studies and cardiac imaging evaluations from patients in the open-label extension, which will inform our decision on further development of ifetroban for this systemic sclerosis indication.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
